Shanghai Shyndec Pharmaceutical Co Ltd (600420) - Total Assets
Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) holds total assets worth CN¥19.23 Billion CNY (≈ $2.81 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Shanghai Shyndec Pharmaceutical Co Ltd (600420) net assets for net asset value and shareholders' equity analysis.
Shanghai Shyndec Pharmaceutical Co Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Shanghai Shyndec Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Shyndec Pharmaceutical Co Ltd's total assets of CN¥19.23 Billion consist of 58.5% current assets and 41.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 20.8% |
| Accounts Receivable | CN¥1.00 Billion | 5.2% |
| Inventory | CN¥1.75 Billion | 9.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥959.52 Million | 5.0% |
| Goodwill | CN¥160.15 Million | 0.8% |
Asset Composition Trend (2001–2025)
This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Shanghai Shyndec Pharmaceutical Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Shyndec Pharmaceutical Co Ltd's current assets represent 58.5% of total assets in 2025, a decrease from 62.3% in 2001.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, up from 19.8% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, a decrease from 6.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 9.1% of total assets.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shanghai Shyndec Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Henan Newland Pharmaceutical Co. Ltd. A
SHE:301277
|
China | CN¥1.77 Billion |
Shanghai Shyndec Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.59 | 2.69 | 1.63 |
| Quick Ratio | 3.03 | 2.18 | 1.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥8.12 Billion | CN¥7.34 Billion | CN¥4.23 Billion |
Shanghai Shyndec Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Shyndec Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.03 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -3.7% |
| Total Assets | CN¥19.23 Billion |
| Market Capitalization | $1.88 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Shyndec Pharmaceutical Co Ltd's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shanghai Shyndec Pharmaceutical Co Ltd's assets decreased by 3.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shanghai Shyndec Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total assets of Shanghai Shyndec Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥19.23 Billion ≈ $2.81 Billion |
-3.65% |
| 2024-12-31 | CN¥19.96 Billion ≈ $2.92 Billion |
+3.12% |
| 2023-12-31 | CN¥19.35 Billion ≈ $2.83 Billion |
-1.42% |
| 2022-12-31 | CN¥19.63 Billion ≈ $2.87 Billion |
+2.94% |
| 2021-12-31 | CN¥19.07 Billion ≈ $2.79 Billion |
+4.49% |
| 2020-12-31 | CN¥18.25 Billion ≈ $2.67 Billion |
+3.47% |
| 2019-12-31 | CN¥17.64 Billion ≈ $2.58 Billion |
+7.13% |
| 2018-12-31 | CN¥16.46 Billion ≈ $2.41 Billion |
+8.52% |
| 2017-12-31 | CN¥15.17 Billion ≈ $2.22 Billion |
+1.04% |
| 2016-12-31 | CN¥15.02 Billion ≈ $2.20 Billion |
+262.91% |
| 2015-12-31 | CN¥4.14 Billion ≈ $605.43 Million |
+8.62% |
| 2014-12-31 | CN¥3.81 Billion ≈ $557.41 Million |
+21.10% |
| 2013-12-31 | CN¥3.15 Billion ≈ $460.30 Million |
+27.41% |
| 2012-12-31 | CN¥2.47 Billion ≈ $361.27 Million |
+65.44% |
| 2011-12-31 | CN¥1.49 Billion ≈ $218.37 Million |
+31.41% |
| 2010-12-31 | CN¥1.14 Billion ≈ $166.18 Million |
+22.41% |
| 2009-12-31 | CN¥927.71 Million ≈ $135.75 Million |
+16.71% |
| 2008-12-31 | CN¥794.87 Million ≈ $116.32 Million |
+11.35% |
| 2007-12-31 | CN¥713.86 Million ≈ $104.46 Million |
+19.45% |
| 2006-12-31 | CN¥597.64 Million ≈ $87.45 Million |
+2.07% |
| 2005-12-31 | CN¥585.51 Million ≈ $85.68 Million |
+13.43% |
| 2004-12-31 | CN¥516.19 Million ≈ $75.54 Million |
+96.94% |
| 2003-12-31 | CN¥262.10 Million ≈ $38.35 Million |
+28.75% |
| 2002-12-31 | CN¥203.58 Million ≈ $29.79 Million |
+15.81% |
| 2001-12-31 | CN¥175.79 Million ≈ $25.72 Million |
-- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate… Read more